Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic LeukemiaKathryn G. Roberts, Timothy P. Hughes, Frank Keller et al.|New England Journal of Medicine|2014Cited by 1.4k
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, Susan Branford et al.|Blood|2013Cited by 705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upRichard A. Larson, H. Kantarjian, Andreas Hochhaus et al.|Leukemia|2012Cited by 440
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al.|Leukemia|2012Cited by 417